Table 1:
Placebo (n=17) |
Dapagliflozin (n=21) |
|
---|---|---|
Age, years | 67 (9) | 67 (9) |
Women, n (%) | 11 (65%) | 14 (67%) |
Men, n (%) | 6 (35%) | 7 (33%) |
Body weight, kg | 98.1 (18.2) | 100.8 (26.5) |
Body mass index, kg/m2 | 34.5 (5.7) | 35.0 (7.2) |
NYHA functional class, n (%) | ||
Class II | 5 (29%) | 7 (33%) |
Class III | 12 (71%) | 14 (67%) |
Left ventricular ejection fraction, % | 63 (6) | 61 (6) |
Resting PCWP <15 mmHg, n (%) | 6 (35%) | 8 (38%) |
Comorbidities | ||
Obesity (BMI≥30), n (%) | 12 (71%) | 15 (71%) |
Hypertension, n (%) | 10 (59%) | 14 (67%) |
Diabetes, n (%) | 1 (6%) | 6 (29%) |
Atrial Fibrillation, n (%) | 6 (35%) | 8 (38%) |
Coronary artery disease, n (%) | 5 (29%) | 4 (19%) |
Medications | ||
Diuretic, n (%) | 12 (71%) | 12 (57%) |
ACEi/ARB/ARNI, n (%) | 4 (24%) | 6 (29%) |
Beta-blocker, n (%) | 9 (53%) | 6 (29%) |
Mineralocorticoid antagonist, n (%) | 6 (35%) | 7 (33%) |
Laboratories | ||
Hemoglobin, g/dl | 13.6 (1.4) | 13.0 (1.5) |
Hematocrit, % | 40.7 (3.5) | 39.1 (4.0) |
eGFR, ml/min/m1.73 | 73 (16) | 71 (17) |
eGFR<60 ml/min/m1.73, n (%) | 3 (18%) | 5 (24%) |
NTproBNP, pg/ml | 118 (76, 226) | 235 (102, 394) |
Blood and Plasma Volumes a | ||
Total blood volume deviation from normal, % | +2 (−2, 9) | +4 (−2, 11) |
Red blood cell volume deviation from normal, % | −6 (−14, 6) | −8 (−20, 1) |
Plasma volume deviation from normal, % | +5 (2, 14) | +12 (5, 22) |
Values represent mean (standard deviation) or median (25th, 75th)
Abbreviations: ACEi – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; ARNI – angiotensin receptor blocker/neprilysin antagonist; BMI – body mass index; eGFR – estimated glomerular filtration rate; NTproBNP – N Terminal pro Brain Natriuretic Peptide; NYHA – New York Heart Association (higher class indicates more severe heart failure severity)
Blood and plasma volumes expressed as deviation from expected normal values based upon weight and sex, negative sign indicates a net deficit compared to normal and positive sign indicates a net excess compared to normal values.